Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma

Atsuya Takeda, Naoko Sanuki, Takahisa Eriguchi, Takashi Kobayashi, Shogo Iwabutchi, Kotaro Matsunaga, Tomikazu Mizuno, Kae Yashiro, Shuichi Nisimura, Etsuo Kunieda

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background and Aims: Stereotactic ablative body radiotherapy (SABR) is a relatively new treatment for hepatocellular carcinoma (HCC). The outcomes of SABR for previously untreated solitary HCC unfit for ablation and surgical resection were evaluated. Methods: Untreated solitary HCC patients treated with SABR were retrospectively studied. Between 2005 and 2012, 221 HCC patients underwent SABR. Among them, patients with untreated solitary HCC, treated with only SABR or SABR preceded by transarterial chemoembolization, were eligible. Based on baseline liver function and liver volume receiving ≥20Gy, 35-40Gy in five fractions was prescribed to the planning target volume surface. Results: Sixty-three patients were eligible, with a median follow-up duration of 31.1 (range 12.0-88.1) months. No patients were lost to follow-up. Twenty patients were treated with only SABR. In 43 patients treated with SABR preceded by transarterial chemoembolization, accumulation of lipiodol in the tumor remained complete in five, a partial defect in 38 on pre-SABR computed tomography. The 1-, 2-, and 3-year local control rates were 100%, 95%, and 92%, respectively; the intrahepatic recurrence-free rates were 76%, 55%, and 36%, respectively; and the overall survival rates were 100%, 87%, and 73%, respectively. Grade 3 laboratory toxicities in the acute, subacute, and chronic phases were observed in 10, 9, and 13 patients, respectively, and ascites occurred in one patient. Conclusions: Local control and overall survival after SABR for untreated solitary HCC were excellent despite the candidates being unfit for resection and ablation. SABR is safe and might be an alternative to resection and ablation.

Original languageEnglish
Pages (from-to)372-379
Number of pages8
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume29
Issue number2
DOIs
Publication statusPublished - 2014 Feb 1
Externally publishedYes

Fingerprint

Radiosurgery
Hepatocellular Carcinoma
Ethiodized Oil
Liver
Lost to Follow-Up
Ascites
Survival Rate
Tomography
Recurrence

Keywords

  • Curative treatment
  • Hepatocellular carcinoma
  • SABR
  • SBRT
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology
  • Medicine(all)

Cite this

Takeda, A., Sanuki, N., Eriguchi, T., Kobayashi, T., Iwabutchi, S., Matsunaga, K., ... Kunieda, E. (2014). Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 29(2), 372-379. https://doi.org/10.1111/jgh.12350

Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. / Takeda, Atsuya; Sanuki, Naoko; Eriguchi, Takahisa; Kobayashi, Takashi; Iwabutchi, Shogo; Matsunaga, Kotaro; Mizuno, Tomikazu; Yashiro, Kae; Nisimura, Shuichi; Kunieda, Etsuo.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 29, No. 2, 01.02.2014, p. 372-379.

Research output: Contribution to journalArticle

Takeda, A, Sanuki, N, Eriguchi, T, Kobayashi, T, Iwabutchi, S, Matsunaga, K, Mizuno, T, Yashiro, K, Nisimura, S & Kunieda, E 2014, 'Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma', Journal of Gastroenterology and Hepatology (Australia), vol. 29, no. 2, pp. 372-379. https://doi.org/10.1111/jgh.12350
Takeda, Atsuya ; Sanuki, Naoko ; Eriguchi, Takahisa ; Kobayashi, Takashi ; Iwabutchi, Shogo ; Matsunaga, Kotaro ; Mizuno, Tomikazu ; Yashiro, Kae ; Nisimura, Shuichi ; Kunieda, Etsuo. / Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. In: Journal of Gastroenterology and Hepatology (Australia). 2014 ; Vol. 29, No. 2. pp. 372-379.
@article{98aa26fd6de84cac946cec4cc26c733e,
title = "Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma",
abstract = "Background and Aims: Stereotactic ablative body radiotherapy (SABR) is a relatively new treatment for hepatocellular carcinoma (HCC). The outcomes of SABR for previously untreated solitary HCC unfit for ablation and surgical resection were evaluated. Methods: Untreated solitary HCC patients treated with SABR were retrospectively studied. Between 2005 and 2012, 221 HCC patients underwent SABR. Among them, patients with untreated solitary HCC, treated with only SABR or SABR preceded by transarterial chemoembolization, were eligible. Based on baseline liver function and liver volume receiving ≥20Gy, 35-40Gy in five fractions was prescribed to the planning target volume surface. Results: Sixty-three patients were eligible, with a median follow-up duration of 31.1 (range 12.0-88.1) months. No patients were lost to follow-up. Twenty patients were treated with only SABR. In 43 patients treated with SABR preceded by transarterial chemoembolization, accumulation of lipiodol in the tumor remained complete in five, a partial defect in 38 on pre-SABR computed tomography. The 1-, 2-, and 3-year local control rates were 100{\%}, 95{\%}, and 92{\%}, respectively; the intrahepatic recurrence-free rates were 76{\%}, 55{\%}, and 36{\%}, respectively; and the overall survival rates were 100{\%}, 87{\%}, and 73{\%}, respectively. Grade 3 laboratory toxicities in the acute, subacute, and chronic phases were observed in 10, 9, and 13 patients, respectively, and ascites occurred in one patient. Conclusions: Local control and overall survival after SABR for untreated solitary HCC were excellent despite the candidates being unfit for resection and ablation. SABR is safe and might be an alternative to resection and ablation.",
keywords = "Curative treatment, Hepatocellular carcinoma, SABR, SBRT, Stereotactic body radiotherapy",
author = "Atsuya Takeda and Naoko Sanuki and Takahisa Eriguchi and Takashi Kobayashi and Shogo Iwabutchi and Kotaro Matsunaga and Tomikazu Mizuno and Kae Yashiro and Shuichi Nisimura and Etsuo Kunieda",
year = "2014",
month = "2",
day = "1",
doi = "10.1111/jgh.12350",
language = "English",
volume = "29",
pages = "372--379",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma

AU - Takeda, Atsuya

AU - Sanuki, Naoko

AU - Eriguchi, Takahisa

AU - Kobayashi, Takashi

AU - Iwabutchi, Shogo

AU - Matsunaga, Kotaro

AU - Mizuno, Tomikazu

AU - Yashiro, Kae

AU - Nisimura, Shuichi

AU - Kunieda, Etsuo

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background and Aims: Stereotactic ablative body radiotherapy (SABR) is a relatively new treatment for hepatocellular carcinoma (HCC). The outcomes of SABR for previously untreated solitary HCC unfit for ablation and surgical resection were evaluated. Methods: Untreated solitary HCC patients treated with SABR were retrospectively studied. Between 2005 and 2012, 221 HCC patients underwent SABR. Among them, patients with untreated solitary HCC, treated with only SABR or SABR preceded by transarterial chemoembolization, were eligible. Based on baseline liver function and liver volume receiving ≥20Gy, 35-40Gy in five fractions was prescribed to the planning target volume surface. Results: Sixty-three patients were eligible, with a median follow-up duration of 31.1 (range 12.0-88.1) months. No patients were lost to follow-up. Twenty patients were treated with only SABR. In 43 patients treated with SABR preceded by transarterial chemoembolization, accumulation of lipiodol in the tumor remained complete in five, a partial defect in 38 on pre-SABR computed tomography. The 1-, 2-, and 3-year local control rates were 100%, 95%, and 92%, respectively; the intrahepatic recurrence-free rates were 76%, 55%, and 36%, respectively; and the overall survival rates were 100%, 87%, and 73%, respectively. Grade 3 laboratory toxicities in the acute, subacute, and chronic phases were observed in 10, 9, and 13 patients, respectively, and ascites occurred in one patient. Conclusions: Local control and overall survival after SABR for untreated solitary HCC were excellent despite the candidates being unfit for resection and ablation. SABR is safe and might be an alternative to resection and ablation.

AB - Background and Aims: Stereotactic ablative body radiotherapy (SABR) is a relatively new treatment for hepatocellular carcinoma (HCC). The outcomes of SABR for previously untreated solitary HCC unfit for ablation and surgical resection were evaluated. Methods: Untreated solitary HCC patients treated with SABR were retrospectively studied. Between 2005 and 2012, 221 HCC patients underwent SABR. Among them, patients with untreated solitary HCC, treated with only SABR or SABR preceded by transarterial chemoembolization, were eligible. Based on baseline liver function and liver volume receiving ≥20Gy, 35-40Gy in five fractions was prescribed to the planning target volume surface. Results: Sixty-three patients were eligible, with a median follow-up duration of 31.1 (range 12.0-88.1) months. No patients were lost to follow-up. Twenty patients were treated with only SABR. In 43 patients treated with SABR preceded by transarterial chemoembolization, accumulation of lipiodol in the tumor remained complete in five, a partial defect in 38 on pre-SABR computed tomography. The 1-, 2-, and 3-year local control rates were 100%, 95%, and 92%, respectively; the intrahepatic recurrence-free rates were 76%, 55%, and 36%, respectively; and the overall survival rates were 100%, 87%, and 73%, respectively. Grade 3 laboratory toxicities in the acute, subacute, and chronic phases were observed in 10, 9, and 13 patients, respectively, and ascites occurred in one patient. Conclusions: Local control and overall survival after SABR for untreated solitary HCC were excellent despite the candidates being unfit for resection and ablation. SABR is safe and might be an alternative to resection and ablation.

KW - Curative treatment

KW - Hepatocellular carcinoma

KW - SABR

KW - SBRT

KW - Stereotactic body radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84884315553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884315553&partnerID=8YFLogxK

U2 - 10.1111/jgh.12350

DO - 10.1111/jgh.12350

M3 - Article

C2 - 23927053

AN - SCOPUS:84884315553

VL - 29

SP - 372

EP - 379

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 2

ER -